قالب:مثبطات المناعة

من موسوعة العلوم العربية

مراجعة 04:06، 20 أبريل 2012 بواسطة أسيل سيوف (نقاش | مساهمات)

(فرق) → مراجعة أقدم | المراجعة الحالية (فرق) | مراجعة أحدث ← (فرق)

اذهب إلى التنقل اذهب إلى البحث

الأدوية المثبطة للمناعة

Intracellular
(initiation)

Antimetabolites	purine synthesis inhibitors: Azathioprine Mycophenolic acid pyrimidine synthesis inhibitors: Leflunomide Teriflunomide antifolate: Methotrexate

Macrolides/ other IL-2 inhibitors	FKBP/Cyclophilin/Calcineurin: Tacrolimus Cyclosporine Pimecrolimus Abetimus Gusperimus

TNF inhibitor	Thalidomide Lenalidomide

Intracellular
(reception)

IL-1 receptor antagonists	Anakinra

mTOR	Sirolimus Everolimus Ridaforolimus Temsirolimus Umirolimus Zotarolimus

Extracellular

Serum target (noncellular)	Complement component 5 (Eculizumab) TNFs (Infliximab Adalimumab Certolizumab pegol Afelimomab Golimumab) Interleukin 5 (Mepolizumab) Immunoglobulin E (Omalizumab) BAYX (Nerelimomab) Interferon (Faralimomab) IL-6 (Elsilimomab) IL-12 and IL-23 (Lebrikizumab Ustekinumab)

Cellular target	CD3 (Muromonab-CD3 Otelixizumab Teplizumab Visilizumab) CD4 (Clenoliximab Keliximab Zanolimumab) CD11a (Efalizumab) CD18 (Erlizumab) CD20 (Afutuzumab Rituximab Ocrelizumab Pascolizumab) CD23 (Gomiliximab Lumiliximab) CD40 (Teneliximab Toralizumab) CD62L/L-selectin (Aselizumab) CD80 (Galiximab) CD147/Basigin (Gavilimomab) CD154 (Ruplizumab) BLyS (Belimumab) CTLA-4 (Ipilimumab Tremelimumab) CAT (Bertilimumab Lerdelimumab Metelimumab) Integrin (Natalizumab) Interleukin-6 receptor (Tocilizumab) LFA-1 (Odulimomab) IL-2 receptor/CD25 (Basiliximab Daclizumab Inolimomab) T-lymphocyte (Zolimomab aritox)

Unsorted	Atorolimumab Cedelizumab Fontolizumab Maslimomab Morolimumab Pexelizumab Reslizumab Rovelizumab Siplizumab Talizumab Telimomab aritox Vapaliximab Vepalimomab

-cept (Fusion)

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug(L3/4)

مجلوبة من «http://www.arabsciencepedia.org/w/index.php?title=قالب:مثبطات_المناعة&oldid=10760»

تصنيفان: